Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

Oral presentation at ERA Congress, the flagship European nephrology meeting Company expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it will present data on paridiprubart, its first-in-class anti-TLR4 antibody, at the 63rd European... The post Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference appeared first on Montreal Gazette .

Original source: Montreal Gazette